Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1151
Embargo will expire:
21-Feb-2018 5:00 PM EST
Released to reporters:
20-Feb-2018 5:05 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 21-Feb-2018 5:00 PM EST

Channels:

Cancer, Cell Biology, Pharmaceuticals, Local - Texas, Local - Houston Metro

170115_McQuade_J.jpg
  • Embargo expired:
    12-Feb-2018 6:30 PM EST

Article ID: 689338

Obesity Associated with Longer Survival for Men with Metastatic Melanoma

University of Texas M. D. Anderson Cancer Center

Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report in a study published in Lancet Oncology of 1,918 patients in six independent clinical cohorts. This effect, referred to as the “Obesity Paradox”, principally manifested itself in men, said Jennifer McQuade, M.D., lead author and instructor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.

Released:
12-Feb-2018 8:05 AM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Dermatology, Obesity, Local - Texas, Local - Houston Metro

LangFueyoGomez.jpg
  • Embargo expired:
    12-Feb-2018 4:00 PM EST

Article ID: 689348

Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy

University of Texas M. D. Anderson Cancer Center

A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology.

Released:
12-Feb-2018 10:05 AM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Immunology, Neuro, Local - Texas, Local - Houston Metro

Hung_Mien_Chie2.jpg
  • Embargo expired:
    12-Feb-2018 12:00 PM EST

Article ID: 689298

Newly Identified Potential Therapeutic Approach Kills Triple-Negative Breast Cancer Cells in Pre-Clinical Study

University of Texas M. D. Anderson Cancer Center

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone cancer that accounts for one-fourth of all breast cancers, could be the focus of a new area of study for immune checkpoint blockade therapy. A team of researchers at The University of Texas MD Anderson Cancer Center revealed that in TNBC a cell process called glycosylation is required for PD-L1/PD1 molecules to interact and identified exactly how and why glycosylation is so crucial.

Released:
9-Feb-2018 12:00 PM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Cell Biology, Immunology, Women's Health, Local - Texas, Local - Houston Metro

henry_kuerer.jpg
  • Embargo expired:
    31-Jan-2018 11:00 AM EST

Article ID: 688660

MD Anderson Study Evaluates Need for Biopsies During Follow-Up Care in Women with Early Breast Cancer

University of Texas M. D. Anderson Cancer Center

In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care. The findings, reported in JAMA Surgery, are the first comprehensive nationwide population-based study regarding the need for breast biopsies performed during follow up after treatment for invasive breast cancer.

Released:
30-Jan-2018 11:00 AM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Women's Health, JAMA, Local - Texas, Local - Houston Metro

  • Embargo expired:
    17-Jan-2018 6:30 PM EST

Article ID: 687969

Presurgical Targeted Therapy Delays Relapse of High-Risk Stage 3 Melanoma

University of Texas M. D. Anderson Cancer Center

A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Patients who had no sign of disease at surgery after combination treatment did not progress to metastasis.

Released:
16-Jan-2018 10:05 AM EST
EXPERT AVAILABLE
Comment

Channels:

Cancer, Dermatology, Surgery, Local - Texas, Local - Houston Metro

JimAllison.jpeg

Article ID: 688037

National Academy of Sciences Awards Kovalenko Medal to Immunotherapy Pioneer Allison

University of Texas M. D. Anderson Cancer Center

Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the 2018 Jessie Stevenson Kovalenko Medal for outstanding research in medical sciences, the National Academy of Sciences announced today.

Released:
17-Jan-2018 11:05 AM EST
EXPERT AVAILABLE
Comment

Channels:

Cancer, Infectious Diseases, Local - Texas, Local - Houston Metro

Navin_N1.jpg
  • Embargo expired:
    4-Jan-2018 12:00 PM EST

Article ID: 687312

New Cancer Model Shows Genomic Link Between Early-Stage and Invasive Breast Cancer Types

University of Texas M. D. Anderson Cancer Center

A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.

Released:
3-Jan-2018 12:05 PM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Cell Biology, Women's Health, Genetics, Cell (journal), Local - Texas, Local - Houston Metro

218669_Chun_S.jpg
  • Embargo expired:
    4-Jan-2018 11:00 AM EST

Article ID: 687389

Small-Cell Lung Cancer Patients Face Barriers to Receiving Standard-of-Care Treatment

University of Texas M. D. Anderson Cancer Center

Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center.

Released:
3-Jan-2018 11:05 AM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Cell Biology, Respiratory Diseases and Disorders, Healthcare, JAMA, Local - Texas, Local - Houston Metro

Andreef2.jpg
  • Embargo expired:
    11-Dec-2017 12:00 PM EST

Article ID: 686509

AML Study Reports High Response Rates with Combination Targeted Therapy

University of Texas M. D. Anderson Cancer Center

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .

Released:
10-Dec-2017 12:00 PM EST
EXPERT AVAILABLE
Comment

Channels:

Blood Disorders, Cancer, Local - Texas, Local - Houston Metro, All Journal News


Showing results

110 of 1151





Chat now!